



PharmaCielo

Nature's Choice From Colombia

February 2019 | TSXV: PCLO



Disclaimer and Cautionary Note Regarding Forward-Looking Statements



Disclaimer and Cautionary Note Regarding Forward-Looking Statements

This presentation ("Presentation") contains information regarding PharmaCielo Ltd. (the "Company", "we", "us" or "our"). Under no circumstances may the contents of this Presentation be reproduced, in whole or in part, in any form or forwarded or further redistributed to any other person. Any forwarding, distribution or reproduction of this document in whole or in part is unauthorized. By accepting and reviewing this document, you acknowledge and agree (i) to maintain the confidentiality of this document and the information contained herein, (ii) to protect such information in the same manner you protect your own confidential information, which shall be at least a reasonable standard of care and (iii) to not utilize any of the information contained herein except to assist with your evaluation of the Company.

This Presentation is for information purposes only and does not constitute an offer to sell or a solicitation of an offer to buy securities of the Company. This Presentation is not, and under no circumstances is to be construed as, a prospectus, offering memorandum, or advertisement or a public offering of securities. The information contained herein has been prepared for the purpose of providing interested parties with general information to assist them in their evaluation of the Company. In this Presentation all dollar values are in Canadian dollars unless stated otherwise.

Certain statements in this Presentation constitute "forward-looking statements," within the meaning of applicable Canadian securities laws. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based on our current beliefs, expectations, assumptions and analyses made by us regarding the future of our business, future plans and strategies, our operational results and other future conditions. Such forward-looking statements can be identified by the use of words, such as "anticipates," or "believes," "budget," "estimates," "expects," or "is expected," "forecasts," "intends," "plans," "scheduled," or variations of such words and phrases or state that certain actions, events or results "may," "might," "will," "would," "could," "should," "continue," or be taken, occur or be achieved. These forward-looking statements relate to, among other things, our future financial performance, financial condition, liquidity, levels of activity, the scalability of our business, our projected production capacity, the potential size of the market for cannabis and cannabinoid derivatives, our competitive advantages as compared to other growing jurisdictions, market strategy, performance, prospects, growth, goals or achievements or other future events. Although we base the forward-looking statements contained in this Presentation on assumptions that we believe are reasonable, these forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual performance and financial results in future periods to differ materially from those anticipated in our forward-looking statements. Without limitation, these risks include risks related to regulation of cannabis and cannabinoid derivatives in Canada, Colombia and other global markets, a lack of significant revenue and dependency on external financing for growth, market demand, and competition. Forward-looking statements do not take into account the effect that transactions or non-recurring or other special items announced or occurring after the statements are made have on our business. For example, they do not include the effect of asset impairments or other charges announced or occurring after the forward-looking statements are made. The financial impact of such transactions and non-recurring and other special items can be complex and necessarily depends on the facts particular to each of them.

Despite a careful process to prepare and review the forward-looking statements, there can be no assurance that the underlying opinions, estimates, and assumptions will prove to be correct. The purpose of the forward-looking statements is to provide the reader with a description of management's expectations regarding our anticipated future performance and may not be appropriate for other purposes. Because of these risks, uncertainties, and assumptions, the reader should not place undue reliance on these forward-looking statements. The Company's forward-looking statements are made only as of the date of this presentation, and except as required by applicable law, the Company undertakes no obligation to update or revise these forward-looking statements to reflect new information, future events or circumstances. The forward-looking statements contained in this document are expressly qualified by this cautionary statement.

Market Research and Public Data: This Presentation also contains or references certain market, industry and peer group data which is based upon information from independent industry publications, market research, analyst reports and surveys and other publicly available sources. Although we believe these sources to be generally reliable, such information is subject to interpretation and cannot be verified with complete certainty due to limits on the availability and reliability of raw data, the voluntary nature of the data gathering process and other inherent limitations and uncertainties. We have not independently verified any of the data from third party sources referred to in this Presentation and accordingly, the accuracy and completeness of such data is not guaranteed.

Future Oriented Financial Information: To the extent any forward-looking information in this Presentation constitutes "future-oriented financial information" or "financial outlooks" within the meaning of applicable Canadian securities laws, such information is being provided to demonstrate the anticipated market penetration and the reader is cautioned that this information may not be appropriate for any other purpose and the reader should not place undue reliance on such future-oriented financial information and financial outlooks. Future-oriented financial information and financial outlooks, as with forward-looking information generally, are, without limitation, based on the assumptions and subject to the risks set out above. Our actual financial position and results of operations may differ materially from management's current expectations and, as a result, our revenue and profitability may differ materially from the revenue and profitability profiles provided in this Presentation. Such information is presented for illustrative purposes only and may not be an indication of our actual financial position or results of operations.

Use of Non-GAAP Measures: This document refers to EBITDA because this information may be used to assess our performance and also determine our ability to generate cash flow. This data is furnished to provide additional information and are non-GAAP measures and do not have any standardized meaning prescribed by GAAP. They should not be considered in isolation as a substitute for measures of performance prepared in accordance with GAAP and is not necessarily indicative of operating costs presented under GAAP.

Large CPG and Pharma Companies are Developing Cannabis Strategies



Beverage

Chemicals

Alcohol

Wellness & Beauty

Pharmaceutical

Tobacco

WINNING PRODUCERS MUST OFFER:

Reliability of Supply

Consistency of Product

Customization of Extract

The biggest CPG manufacturers need unique, quality inputs at scale



PharmaCielo

BUILT TO SUPPLY THE WORLD'S GLOBAL END-PRODUCT COMPANIES & LARGE CHANNEL DISTRIBUTORS WITH MEDICINAL-GRADE CANNABINOID EXTRACTS

Expertise Necessary to Build Global Cannabis Supplier

Engaged Board and Knowledgeable Management: Technical, Cultivation, and General Enterprise Experience

Technical

100+ years of medical and chemical engineering experience

Dr. Delon Human

Global Head, Health and Innovation

- Served as secretary-general of the World Medical Association and advisor to secretary-general of UN and director-general of WHO
- Served as special envoy to the UN of the International Food and Beverage Alliance

Dr. Camilo Alberto Ospina Saldarriaga

Head of Product Development

- Founder of Ubiquo Telemedicina, Colombia's only established provider of telemedicine services

Henning Von Koss

Director

- Served as senior vice president of Latin America for Bayer Material Science, president and head of healthcare in Andean region

Cultivation

100+ years of managing large-scale cultivation operations

Federico Cock-Correa

CEO Colombia, Director

- Founder of Ecoflora, a plant-based wellness extracts company, member of board of directors of Colombian Flower Exporters Association

Marcelo Antunes de Siqueira

COO (Nursery & Propagation Centre)

- Oversaw the first world-class bromeliad breeding program in Latin America leading to multiple patents

Carlos Manuel Uribe

Chairman of the Board, PharmaCielo Colombia

- Chairman of ASOCOLFLORES, Colombian Association of Flower Exporters; former general manager of Flores El Capiro, the world's largest exporter of flowers by sea freight
- Board member of Colombia's largest avocado and pineapple producer

General Enterprise

200+ years of senior leadership in financial, tobacco and pharmaceutical industries

David Attard

CEO, Director

- Former senior vice president, corporate strategy & business innovation at President's Choice Financial, a subsidiary of Loblaw Companies Limited

Scott Laitinen

CFO, Director

- Former chief risk and operating officer of President's Choice Financial

Simon Langelier

Chairman of the Board, PharmaCielo Ltd.

- Former managing director of Philip Morris Colombia
- Independent board member of Imperial Brands PLC

Colombia: An agricultural powerhouse

2nd largest supplier
of cut flowers



3rd largest supplier
of coffee



5th largest supplier
of bananas



Colombia is committed to becoming the world's leading supplier of cannabis extracts

Colombia: Structural Cost Advantage

Ideal Natural Conditions

- One of only a few places globally where you can efficiently grow cannabis
- Natural & consistent 12-hour light cycle and temperate climate means:
 - Minimal energy costs
 - Extremely low carbon footprint
 - High production efficiency
- Natural water reservoirs reduce costs

Optimal Economic and Regulatory Conditions

- Agricultural labour costs 25% of the cost in the United States
- Cost to build a greenhouse well below North American average
- Colombia has 44% of the world's quota for medicinal cannabis¹
- History of building large-scale agricultural industries
- Government has targeted cannabis as a growth industry like they did with cut flowers

1) International Narcotics Control Board, 2018



Highly educated and skilled agricultural workforce


Licensed and Operational Today

Licensing Regime

1. Cannabis Manufacturing Licence ✓
2. Cannabis Psychoactive Cultivation Licence ✓
3. Cannabis Non-Psychoactive Cultivation Licence ✓

Genetic Registration

- 10 strains registered with the national cultivar with an additional 20 expected by end of February 2019
- 186 strains registered in PharmaCielo germplasm bank as proprietary source material



Fully Licensed for commercial sales worldwide

The largest cultivator in Colombia of both CBD- and THC-dominant cannabis

Highly Scalable Business Model

Company-Owned and Cultivation Facilities Under Contract:

Nursery & Propagation Centre	12 Hectares open-air greenhouses	0.48 Million KG¹ flower capacity per year
Company-Owned with Indigenous Growers	4 Hectares open-air greenhouses	0.15 Million KG flower capacity per year
Contract Growers	123 Hectares open-air greenhouses	4.90 Million KG flower capacity per year
Total	139 Hectares open-air greenhouses	5.53 Million KG flower capacity per year

1) Conservative calculation of capacity for illustrative purposes only (based on 1,000 grams/sq. metre, four annual growing cycles)

Contract growing is a proven model in mature industries to scale supply



Oil Extraction Phase One

2,300 m² full-scale production facility (complete by Q2 2019)

12 metric tonnes of refined cannabis oil capacity per year

GMP certification expected by Q3 2019

ISO 9001 pre-audit complete



Building inventory for 2019 market distribution

Increasing Production Capacity

By the end of 2019 we expect to:

have 20 hectares planted.

have our GMP certified production facility completed. Capable of 12 metric tonnes of cannabis oil a year.





PharmaCielo

Nature's Choice From Colombia

Growth Strategy

Strategic Approach to Long-Term Growth

Sales Channel Opportunities

Bulk CBD & THC Oil

Europe, Canada, and South America

**Co-Branding PharmaCielo
Inside**

High-grade oil for large channel distributors, pharma, and CPG companies

Branded Products

Global Market



Today

Long-Term

Margin expansion as we move up from input to end-product

Near-Term Target Markets



Global Expansion Under Development




Colombia



Mexico



Uruguay



Italy



Canada



Argentina

PharmaCielo is in active negotiation to enter additional markets in 2019

Capital Structure¹

Shares Outstanding:	94.8 Million
Fully Diluted S/O:	110.5 Million
Recent Price:	CDN\$8.43
Fully Diluted Market Cap:	CDN\$931.5 Million
Cash:	CDN\$41.4 Million ²
Insider Ownership:	~20%

1) As of January 31, 2019

2) From Listing Statement. Converted to CAD at \$1.32 as of January 9, 2019



PharmaCielo

Nature's Choice From Colombia

February 2019 | TSXV: PCLO

